Various randomized controlled trials (RCT) (mainly without the stratification based on EGFR status) have been conducted to study the efficacy of the adding molecular-targeted therapies to chemotherapeutics for the treatment of advanced gastric cancer (Table 1). This evidence concerns the gene EGFR and gastric cancer.